Growth factor and oncogene signalling pathways as targets for rational anticancer drug development
- 1 October 1991
- journal article
- review article
- Published by Elsevier in Clinical Biochemistry
- Vol. 24 (5) , 385-397
- https://doi.org/10.1016/s0009-9120(05)80014-1
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Platelet-derived growth factor blocks the increase in intracellular free Ca2+ caused by calcium ionophores and a volatile anesthetic agent in Swiss 3T3 fibroblasts without altering toxicityToxicology Letters, 1991
- Genetic and cellular basis of multistep carcinogenesisPharmacology & Therapeutics, 1990
- Oncogenes, Growth Factors, and Signal TransductionNew England Journal of Medicine, 1989
- Irreversible inhibition of v-src tyrosine kinase activity by herbimycin a and its abrogation by sulfhydryl compoundsBiochemical and Biophysical Research Communications, 1989
- Does inositol tetrakisphosphate play a role in the receptor-mediated control of calcium mobilization?Cell Calcium, 1989
- Contribution of external and internal Ca2+ to changes in intracellular free Ca2+ produced by mitogens in swiss 3T3 fibroblasts: The role of dihydropyridine sensitive Ca2+ channelsBiochemical and Biophysical Research Communications, 1989
- The antiproliferative effects of staurosporine are not exclusively mediated by inhibition of protein kinase CBiochemical and Biophysical Research Communications, 1988
- A PDGF receptor domain essential for mitogenesis but not for many other responses to PDGFNature, 1988
- Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivativesBiochemical and Biophysical Research Communications, 1987
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986